Core Scientific's largest shareholder, Two Seas Capital, opposes the acquisition protocol by CoreWeave, deeming the $9 billion valuation too low and the transaction structure overly risky. This shareholder holds a 6.3% stake and supports Core Scientific's independent operations, calling for any acquisition to reflect its true value.